Utilising this approach, protein quantification within tumour samples in the TCGA cohort12 via reverse phase protein array (RPPA) reveals that presumed active YAP levels are higher in patients affected with any common, canonical Hippo kinase module inactivating mutation (NF2, LATS1/2, SAV1) (Figure 2A). This evidence concerns the gene YAP1 and neoplasm.